

# PSYCHOPHARMACOLOGY

## And Substance Abuse Newsletter

Division 28 - American Psychological Association

Spring, 1996

Volume 29, No. 1



## From the President's Desk ...

**Stephen C. Fowler, Ph.D.**  
President, Division 28

### Some Thoughts on the Prescription Privileges Debate

Although Division 28 has as yet taken no official position on whether or not psychologists should seek prescription privileges, our division has strongly supported, and continues to support the concept that extensive training will be required for most psychologists to safely and effectively use psychotropic medications in discharging their professional mental health care responsibilities. Given the fact that the APA Council of Representatives has now endorsed the idea that prescribing psychotropic medications is a professional skill that psychologists may acquire to improve treatment outcomes, and given the additional fact that several states are actively working on enabling legislation to grant prescription privileges to psychologists, it seems that all members of APA will sooner or later have to make a choice on the issue.

In this context, rather than coming forth with an essay to persuade you to be for or against prescription privileges, I want to raise an issue that I think has been neglected in this debate. This is the role of research training in the preparation of health care professionals. Some critics of prescription privileges suggest that by embracing drugs as a form of therapy psychologists will cease to rely on their function-based treatments which emphasize patients' responses and environmental contexts. I personally do not believe this will happen as long as research training remains a core value in professional psychology that is equal to training in therapy techniques and skills.

Basic biobehavioral research is now amply demonstrating that the dichotomies of the past are simply empirically inaccurate. Dichotomies such as "organic" versus "functional" or "nature" versus "nurture" are clearly archaic. If we continue to support relevant research training and research activity, the dichotomy inherent in the term "psychopharmacology" will be increasingly recognized as false. For example, functional imaging studies of the human brain (PET, Functional MRI, SPECT) have permitted the identification of brain activity associated with specific cognitive and motor tasks, and changes in brain function have been observed in relation to motor learning, perception, psychotherapy, and drug treatment. When viewed together these studies demonstrate the functional correlations among brain events, environmental events, personal histories (genotypic and phenotypic), and drug treatments. For instance, functional interrelations are demonstrable by measurement techniques that cut across older disciplinary boundaries, as in studies that combine concurrent analyses of neuronal activity, stimulus-

response learning, and pharmacological manipulations. As understandings of these experimental preparations increasingly emerge it will be the clinician's task to derive information from these and other spheres of knowledge and apply it to promote better health in their patients. The results of contemporary scientific research on brain, behavior and drugs is clearly implying that approaches exclusively based on the old dichotomies are incomplete. Research trained clinicians are more likely to be exposed to these various spheres of knowledge and to accept the proposition that drug therapy and psychotherapy go together.

In addition to providing the opportunity to advance biobehavioral knowledge, research training teaches us the limitations of current knowledge. Good research training thus imparts skepticism, which then engenders a stringent "show-me-the-facts" disposition. Research trained clinicians are more likely than technically trained clinicians to respond to the facts of treatment outcomes and to select methods that have the most beneficial effects.

One of the paradoxes of the national rush towards the "industrialization" of health care (i.e., managed care) is that, on the one hand, biomedical research will likely receive less support as large health care companies driven by profit crowd out research hospitals associated with medical schools, while, on the other hand, companies will need research into the comparative efficacy and efficiency of various treatments in order to

(cont'd, p. 2)

### IN THIS ISSUE

Division 28 Convention Awardees .....	page 3
Division 28 Convention Scheduling .....	page 4
Conference on Drug Abuse .....	page 5

# President's Letter (cont'd)

maximize profits. To the extent that such research is supported, psychologist with strong research training would seem to hold an advantage over professionals less well trained in the tools of scientific inquiry. In my view, psychologists with strong training in scientific research will fare better as prescribers of medication and as survivors in the health care environments of the future.

## APA Council of Representatives Meeting

Feb. 16-18, 1996

M. Marlyne Kilbey, for Alice Young,  
Council Representative

I attended the winter, 1996 meeting of the APA Council of Representatives as Alice Young is on sabbatical this term. The Council deliberated 64 agenda items. The task was facilitated by a consent agenda of about 15 items that were quickly endorsed. Items of particular interest to Division 28 members included, Prescription Privileges, Report of the BEA Working Group on Psychopharmacology on Level 1 and Level 2 training, and the Dual Membership Proposal. Of general interest to APA members are the public information campaign, the 1995 membership data, and the 1996 final budget. Some of this information will be known to you, as the APA Monitor, for example, has already covered the dual membership provisions. Nevertheless, I'll provide a quick overview of these issues for Division 28 newsletter readers.

The Dual Membership Proposal was introduced by the Board of Scientific Affairs, Chaired by Bob Balster, former Division 28 President, in response to APA's dwindling proportion of scientific/academic members in comparison to its professional/practice members. It will allow for a 25% reduction in APA dues to members who are members of APS or any organization in the Federation of Behavioral, Psychological, and Cognitive Sciences, for example, Psychonomic Society, Association for Behavior Analysis. The motion passed overwhelmingly and seemed to set a tone for the meeting of cooperation between the sometimes antagonistic scientist/academic and professional/practice council members. Another dues related motion would charge a \$50 annual service fee to dues-exempt members (i.e. persons over 65 who have 25 years of membership in APA and who request dues exemption) to pay for the Monitor and American Psychologist. This motion generated heated debate and was referred to committee for further work. A motion to increase the amount of member's dues that reverts to his/her primary division from \$2 to \$5 was defeated.

The Prescription Privileges document is the work of a CAPP Taskforce that was referred to Council for review, discussion and approval of its model legislation for prescriptive authority and recommended curriculum for postdoctoral training. At the pre-council caucuses, it became obvious that there were substantial concerns about this item and a novel strategy was fashioned to get it through council by

## Division Business

The ballot for APA president was mailed May 15, 1996. The marked ballot must be returned by July 1, 1996. At its recent meeting the Executive Committee endorsed two candidates on the ballot: Martin E.P. Seligman and Richard Suinn. I have met and have had extended conversations with both of these outstanding individuals during the course of my career. Both would reflect well Division 28's emphasis on research and rigorous scientific training. Marty Seligman

Ron Fox who chaired the CAPP Taskforce. Fox argued that the model legislation and curriculum were needed by groups already working on legislation and asked that the item be passed as a working document with the understanding that it would go to APA's Boards of Educational, Professional and Scientific Affairs for comment and final wording and come back to Council in August for a final vote. With this understanding, the interim document passed. Division 28 had argued at the scientific and the women's caucus meetings that the document needed to be revised to include a definition of demonstrated knowledge that made it clear that prerequisites for entering into a post-doctoral course in Psychopharmacology would be obtained by successful completion of a planned sequence of courses at a regionally accredited institution of higher education or a planned sequence of continuing education courses offered by an accredited institution of higher learning or accredited provider of continuing education and satisfactory performance on a standard examination covering the content of such a program. We also argued that the post doctoral program itself needed to be offered by a regionally accredited institution of higher learning with an appropriate faculty and facilities for the required didactic training and clinical experiences. In our view, the failure to spell out these requirements could lead to the proliferation of sub-standard, self-study programs which would lead to increased misprescription of psychoactive medications. Division 28's language which was similar to that of the BSA and the Committee for Women in Psychology was sent to the Various Board of APA for the further consideration. At this point in time, these issues are still unresolved and the item, with all issues resolved one hopes, will come back to council at the August convention.

The BEA Working Group reported the completion of modules of training for a basic course in Psychopharmacology for psychologists. They outlined their plans for developing model curriculum for didactic and experiential training in Psychopharmacology for psychologists wishing to collaborate with physicians and other prescribing professionals in the management of patients' medications and psycho-social therapies. This item required no action of Council.

Council voted to set aside 1M to support a

is, of course, an internationally known psychopathology theorist and originator of the learned helplessness concept. Dick Suinn is a scientist-practitioner clinician, and was for 20 years chair of his department at Colorado State University. When I was Council Representative for Division 28, I had the opportunity to observe first hand Dick Suinn's considerable oratory skills and affable style. Having been a mayor of Fort Collins, Colorado, he is experienced in leading a diverse constituency. Details on these APA presidential candidates can be found in the May, 1996 issue of the APA Monitor.

Public Education Campaign which represents psychologists as mental health professionals who can help with major life problems (belligerent children, job loss, coping with major health problems) and \$300,000 to duplicate certain aspects of the Traveling Psychology Exhibit for permanent display in the new AAAS building and the APA building. These funds will come from the 1996 budget.

As of 10/95, APA's total membership was 138,178 of whom 96,000 are affiliated with a division or divisions. There were 5,700 new members, and 2,900 member losses for nonpayment of dues, resignations, and deaths. 50,000 student affiliates would seem to assure APA's future growth.

## POSTDOCTORAL RESEARCH FELLOWSHIP IN SUBSTANCE ABUSE

Three research fellowships positions (2-3 yrs) are available in a stimulating and productive laboratory and clinic. The first position - responsibilities will be to participate in studies on the behavioral and pharmacological treatment of opioid and heroin dependence. Includes research on new pharmacotherapy, buprenorphine, as well as behavioral treatment. For this position contact: Warren K. Bickel, Ph.D.

The second position - is to conduct laboratory self-administration studies in humans and/or treatment studies of smoking cessation. For this position contact: John R. Hughes, M.D.

The third position entails participating in the development, conduct, and publication of studies on behavioral treatments for cocaine dependence. Participation in conducting laboratory studies examining factors influencing human cocaine self-administration is also possible. For this position contact: Stephen T. Higgins, Ph.D.

For all positions, applications must have completed doctoral training in psychology or pharmacology and have research experience. Individuals from disadvantaged groups are encouraged to apply. Competitive stipends. Send letter of interest, vita, and letters of reference to the individual named above at:

The University of Vermont  
Dept. of Psychiatry  
Human Behavioral Pharmacology Laboratory 38  
Fletcher Place  
Burlington, VT 05401-1419

# Animal Research Information

## Submitted by:

Christine A. Sannerud, Chair

Div. 28 Committee on Animal Research

## New Guide for the Care and Use of Laboratory Animals

The new edition in more than 10 years of the Guide for the Care and Use of Laboratory Animals will be available to researchers in a few months. Prepublication copies of the new version were distributed to federal agency sponsors in January 1996. The Guide was first published in 1963 and has been revised 7 times to keep scientists and research institutions informed about advances and developments in laboratory animal care. All institutions that receive grants from the Public Health Service (PHS) are required to follow recommendations put forth in the Guide and to adopt supplemental principles appended to it. The PHS supports most projects in the US that involve animal research. Final versions of the Guide will be available to the public in print and electronic forms. There are also plans to

include the Guide on the National Academy's Home page on the World Wide Web, and on the US Department of Agriculture Animal Welfare Information Center CD-ROM.

## "March for Animals" planned in Washington, DC

The American Anti Vivisection Society has put a notice in its Activate for Animals describing its plans for "tens of thousands of animal rights activists and movement leaders" to spend the week of June 18-24 in Washington, DC as part of "Animal Awareness Week." The event will be sponsored, in part, by most of the larger and well-recognized animal rights groups, including the Humane Society of the US, PETA, Animal Protection Institute, In Defense of Animals, the Doris Day Animal League, and the ASPCA, along with many smaller organizations. According to Activate for Animals, activities will include a March, a World Congress for Animals and a National Lobby Day for Animals. The notice said the activities will expose "the untold suffer-

ing and injustice endured by millions of animals every day. World Animal Awareness Week promises to be turning point for our movement." A similar animal rights march was held in the summer of 1990 and was sponsored by many of the same groups. An estimated 24,000 people attended that rally.

## USDA Public Meetings on the Animal Welfare Act Regulations

The USDA held public meetings in Kansas City and St. Louis in February to discuss the current Animal Welfare Act (AWA). The general consensus was that better enforcement of the regulations are needed, not additional or different federal standards. Some ideas and recommendations included improved quality, consistency and uniformity of USDA inspections; recognition of facilities that exceeded minimum standards; concentration on below-standard USDA licensees and faster resolution of noncompliance situations. Input from these meetings and one to be held soon in Washington (no date set) will assist the USDA in finalizing legislative and regulatory proposals planned for the near future.

## Committee on Nominations and Awards

The Division of Psychopharmacology and Substance Abuse (28) of the American Psychological Association (APA) annually gives three awards to recognize excellence in Psychopharmacology and Substance Abuse research.

The Award for Outstanding Basic Psychopharmacological Research on Affective Disorders is to recognize outstanding career research contributions in the area of psychopharmacology/behavioral pharmacology and affective disorders research on affective disorders by a senior investigator. This year's winner was Dr. James H. Woods, Professor of Psychology at the University of Michigan, for his groundbreaking research and leadership in both opioid and benzodiazepine behavioral pharmacology. The award is sponsored by Wyeth-Duphar B.V.

The Young Psychopharmacologist Award is intended to honor a young scientist doing original, meritorious work in psychopharmacology and to encourage excellence in research at the interface between the disciplines of pharmacology and psychology. This year's winner was Dr. Jenny Wiley, Assistant Professor of Pharmacology and Toxicology at the Medical College of Virginia. Dr. Wiley was recognized for her original research in two areas: 1) drugs that act through excitatory amino acid mechanisms to produce anxiolytic-like effects; and 2) cannabinoids. The award is sponsored by Wyeth-Ayerst.

The Robert and Phyllis Levitt Award recognizes the best doctoral thesis in psychopharmacology and substance abuse. This year's winner was Michael R. Weed, Ph.D., University of Chicago. Dr. Weed received the award in recognition of his doctoral thesis investigating D1 receptor mechanisms in drug self-administration. The award is supported by a contribution from Robert and Phyllis Levitt and the American Psychological Foundation.

We congratulate this year's outstanding winners and gratefully acknowledge the sponsors.

William L. Woolverton, Ph.D.

Professor and Director

Division of Neurobiology and Behavior Research

Department of Psychiatry and Human Behavior

University of Mississippi Medical Center

## PSYCHOPHARMACOLOGY And Substance Abuse Newsletter

Division 28 - American Psychological Association

### EDITORIAL POLICY

*Psychopharmacology and Substance Abuse Newsletter* is a quarterly publication of Division 28 of the American Psychological Association. It is devoted to keeping its members informed about the activities of Division 28 and to the news and comments concerning all aspects of Psychopharmacology and Substance Abuse.

Comments, brief articles (1,000-2,000 words), and letters are welcome and will be considered for publication as space allows. Articles, comments, announcements, and advertisements should be sent to:

James P. Zany, Ph.D.  
Dept. of Anesthesia and Critical Care  
University of Chicago  
MC 4028  
5841 S. Maryland Ave.  
Chicago, IL 60637

Submissions should be submitted in both hard copy (letter quality) and diskette. FAX submissions are discouraged.

Deadlines are March 15 (Spring), June 15 (Summer), September 15 (Fall), and December 15 (Winter).

## 1996 APA Division 28 Convention Program Schedule

### SUNDAY - 8/11/96

Time	Location	Chair/Speaker	Title	Type of Presentation
9:00 - 10:50	Conv. Cntr. 205D	M. Stitzer & H. Lando	AHCPR Clinical Practice Guidelines for Smoking	Symposium
11:00 - 11:50	Conv. Cntr. 201C	Donald Calsyn	Efficacy of Using Contingency Management Procedures in Drug Abuse Treatment	Invited address New Fellows
12:00 - 12:50	Conv. Cntr. 206E	James Wood	Kappa Opioid Receptors	Invited address Solvay-Duphar
1:00 - 1:50	Conv. Cntr. 206B	Robert Balster	Scientific Perspectives on Inhalant Abuse	Invited address
2:00 - 2:50	Conv. Cntr. 103B	Aaron Bitensberg	An Operant Runway Model of Opiate Drug Abuse	Invited address New Fellows
3:00 - 3:50	Conv. Cntr. 103B	Jack Henningfield	Public Health Policy Foundation: Up in Smoke - Nicotine Research Travails	Invited address
4:00 - 4:50	Conv. Cntr. 103B	Stephen Fowler	Clinical and Preclinical Studies of Typical and Atypical Neuroleptics	Presidential address
5:00 - 5:50	Conv. Cntr. 103B	Stephen Fowler	Division 28 Business Meeting	Business Meeting

### MONDAY - 8/12/96

Time	Building	Chair/Speaker	Title	Type of Presentation
9:00 - 9:50	Crowne Plaza Niagara	Jenny Wiley	Behavior Pharmacology of NMDA Antagonists: Therapeutic Implications	Invited address: Young Psychopharmacologist
10:00 - 11:50	Conv. Cntr. 103B	Ross Greene	Psychopharmacology and Substance Abuse in ADHD	Symposium
10:00 - 11:50	Conv. Cntr. 202C	Frank White	Neuroadaptations Resulting from Psychomotor Stimulant Addiction and Withdrawal	Symposium
12:00 - 1:50	Conv. Cntr. 103B	W. Bickel & G. Madden	Laboratory Models for Understanding Drug Abuse	Symposium
1:00 - 2:50	Conv. Cntr. Exhibit Hall	Douglas Marlowe	Behavioral Pharmacology and Substance Abuse Poster Session	Poster Session
2:00 - 3:50	Conv. Cntr. 103B	W. Bickel & N. Petry	Current Trends in the Pharmacological Treatment of Opioid Abuse	Symposium
4:00 - 4:50	Conv. Cntr. 103B	George Koob	Neurobiology of Drug Addiction	Invited address
5:00 - 5:50	Crowne Plaza			Social Hour

### TUESDAY - 8/13/96

Time	Building	Chair/Speaker	Title	Type of Presentation
9:00 - 10:50	Conv. Cntr. 206A	Stephen Higgins	Motivating Behavior Change Among Illicit-Drug Abusers: Contingency Management Interventions	Symposium
11:00 - 11:50	Crowne Plaza Hamber	R. Lamb & K. Kirby	Shaping Compliance in Drug Abuse Treatment	Symposium
12:00 - 12:50	Conv. Cntr. 104D	Nick Goeders	Stress, the HPA Axis and Cocaine Self-administration in Rats	Invited address New Fellows
1:00 - 2:50	Conv. Cntr. 202C	J. Zaczyn & S. Fowler	Laboratory Studies in Behavioral Pharmacology	Paper Session Levitt Award
2:00 - 2:50	Conv. Cntr. 202A	M.J. Rotheram-Borus	Clinical Research in Addictions: Issues Regarding Children and Families	Paper Session

Program information for the 1996 APA Convention also has been electronically posted on the APA Home page. You can access the APA Home page at <http://www.apa.org>

## Additional Information of Interest to Division 28 Members Regarding the 1996 Convention

Kimberly C. Kirby, Ph.D.

Program Chair

### Hospitality Suite and Social Hours

We plan to host a hospitality suite for members and participants in Division 28 in the Royal York Hotel on Sunday and Monday evenings. The room number will be announced at Division 28 presentations, or you can check the hospitality suite listing at the Convention Center for the specific location and hours. We are also co-sponsoring a social hour in the Crowne Plaza Hotel with the Science Directorate and other Science Divisions on Monday from 5:00 - 5:50 p.m.

### Focus on Science

Focus on Science in an experimental program taking place at the 1996 APA convention. Scientific programming will be compressed into 3 days (Sunday, August 1) through Tuesday, August 13) instead of the usual five. By compressing the program APA hopes to make attending the convention easier and more affordable for members. The three days of the Focus on Science programming will feature exceptional scientific presentations and other events of interest to psychological scientists.

This year the following eight APA divisions are participating with Division 28 in the compressed science programming: Division 3 (Experimental), 6 (Behavioral Neuroscience and Comparative), 7 (Developmental), 8 (Society of Personality and Social Psychology), 14 (Society for Industrial and Organizational Psychology), 21 (Applied Experimental and Engineering), 25 (Experimental Analysis of Behavior). Among the speakers who will present during this time are James H. Wood, Ph.D. (Solvay Duphar Award winner), Robert L. Balster,

Ph.D., George Koob, Ph.D., Harry A. Lando, Ph.D., Gary Latham, Ph.D., Alexandra Logae, Ph.D., Abigail Stewart, Ph.D., and Francis J. White Ph.D. A complete listing of the eight divisions participating in the focus on Science program can be found in the APA convention program as well as in the Focus on Science program book which can be obtained from the APA Science Directorate in late June or during the convention by stopping by the Science Directorate information booth in the Toronto Convention Centre.

### Conference on Drug Abuse

Jaylan S. Turkkan, Ph.D., Chief, Behavioral Sciences Research Branch, National Institute on Drug Abuse

The National Institute on Drug Abuse (NIDA) and the American Psychological Association (APA) Science Directorate are collaborating to cosponsor a Conference on Drug Abuse (CODA). The conference will be August 9th through the 13th and will be held in conjunction with the 1996 APA Convention in Toronto. The goals of this mini-convention like conference are to focus attention on drug abuse and drug abuse research, to disseminate the latest and most important research findings, to encourage new research, researchers and research collaborations, and to stimulate communication among researchers in different areas and other professionals who are involved with the issues of drug abuse.

A variety of activities are being planned including 15 keynote presentations, and over a hundred symposia, education workshops, papers, poster sessions and other special activities. Training and informational sessions

with NIDA staff and opportunities to find about research activities, support and professional development will also be part of the conference. Dr. Alan Leshner, Director of NIDA, will give a special address Saturday, August 10 at 4pm which will be followed by a gala reception to which all are invited.

Approximately 15,000 to 20,000 people are expected to attend the APA convention including clinicians, researchers, educators, policy and planning professionals and graduate students. APA has 51 different interest oriented divisions focusing on a vast range of psychological, psychiatric, behavioral, neuropsychological, social, and developmental areas. The Conference will provide useful drug abuse research information for professionals in all of these areas.

The latest information about the Conference will be available through the NIDA home page on the Internet (<http://www.nida.nih.gov>). Information on registration for the APA convention can be obtained directly from the APA [1-800-374-2721]; there is no separate registration for the Conference on Drug Abuse. The 1996 Conference on Drug Abuse is an important event and we hope that you will join us.

Editor's note: Division 28 is responsible for hosting Robert L. Balster, Ph.D., George Koob, and Jack Henningfield, Ph.D. in conjunction with this programming (see schedule below). A complete listing of sessions and events associated with the Conference on Drug Abuse can be found at the APA registration table or the NIDA exhibit booth (#627-629)

### Conference on Drug Abuse: Invited Speakers

#### SATURDAY - 8/10/96

Time	Location	Chair/Speaker	Title
1:00 - 1:50	Crowne Plaza Niagara	Thomas J. Coates	Drug Abuse and HIV Transmission: What's needed to Protect the Next Generation
2:00 - 2:50	Crowne Plaza Ballroom B	Jose Szapocznik	Families and Cultures in Drug Abuse Prevention and Treatment
3:00 - 3:50	Crowne Plaza Ballroom B	Marilyn M. Lindehan	The Development and Dissemination of Treatments for Drug Abuse
4:00 - 4:50	Crowne Plaza Ballroom B	Alan L. Leshner	Behavioral Science and Drug Abuse: Half a Century of Productive Partnership

#### SUNDAY - 8/11/96

Time	Building	Chair/Speaker	Title
10:00 - 10:50	Conv. Cntr. 104B	Meyer D. Glantz	Etiology Research: A Meeting to Launch a New Coalition
12:00 - 12:50	Conv. Cntr. 203A	Marilyn Carroll	Animal Models for the Prevention and Treatment of Drug Abuse
1:00 - 1:50	Conv. Cntr. 206B	Robert L. Balster	Scientific Perspectives on Inhalant Abuse
2:00 - 2:50	Westin HC Pier 4	David F. Musto	How Public Attitudes have Impacted Drug Abuse Research in the 20th Century
3:00 - 3:50	Conv. Cntr. 103B	Jack Henningfield	Public Health Policy Foundation: Up in Smoke - Nicotine Research Travails
4:00 - 4:50	Conv. Cntr. 205D	George DeLeon	Therapeutic Community: Applications in Research and Practice

#### MONDAY - 8/12/96

Time	Building	Chair/Speaker	Title
10:00 - 10:50	Conv. Cntr. 104D	James D. Colliver	Community Epidemiology Working Group on Drug Abuse: Front-line Surveillance
1:00 - 1:50	Conv. Cntr. 103A	Robert J. Pandia	Why Do People Use, Abuse, and Become Dependent on Drugs?
2:00 - 2:50	Conv. Cntr. 103A	Dante Cicchetti	A Developmental Psychopathology Perspective on Drug Abuse
3:00 - 3:50	Conv. Cntr. 104D	Gilbert J. Botvin	Adolescent Drug Abuse Prevention: Current Findings and Future Directions
4:00 - 4:50	Conv. Cntr. 103B	George F. Koob	Neurobiology of Drug Addiction

---

# APA Convention Workshops

## 133 Recent Advances in Pharmacotherapy for Adults: Implications for Psychology Practice -- Co-sponsored with APA Division 28

This INTERMEDIATE workshop will provide practicing psychologists with a working knowledge of commonly-used and new-generation drug therapies for the treatment of prevalent psychological disorders. These disorders include depression, anxiety syndromes, eating disorders, and alcohol abuse. The workshop is partially supported by unrestricted educational grants from pharmaceutical companies.

**FOR PSYCHOLOGISTS or RESEARCHERS** who want up-to-date information about widely-used traditional and newer generation drug treatments. A background in psychopharmacology is not necessary.

### *THIS WORKSHOP IS DESIGNED TO HELP YOU:*

1. Gain practical knowledge about drug treatments for symptoms of common psychological disorders seen in clinical practice;
2. Define therapeutic and adverse effects of drug treatments;
3. Acquire current empirically-based information on the prevalence of the four disorders, risk factors for their onset, and drug-responsive symptom patterns; and
4. Build your own clinical model for determining if and when drug treatment may be indicated for these commonly-seen disorders.

**LEADERS:** Carolyn M. Mazure, PhD, and Stephanie O'Malley, PhD, Department of Psychiatry, Yale University School of Medicine, New Haven, CT; Madelyn H. Fernstrom, PhD, Department of Psychiatry and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA; Michael W. Otto, PhD, Massachusetts General Hospital and Department of Psychology, Harvard Medical School, Boston, MA

**FEES:** Member/CPA Advance: \$155.00 On Site: \$180.00 **ENROLLMENT LIMIT:** 75 **TIME:** 9 a.m. - 5 p.m.  
Non-member Advance: \$175.00 On Site: \$200.00 **CE CREDITS:** 7

**DATE:** Sunday, August 11, 1996

---

## 109 Scientific Basis of Drug Abuse Treatment -- Co-sponsored with APA Divisions 28 and 50

The biological and scientific background for substance abuse disorders will be presented in this INTERMEDIATE workshop. The pharmacology of abused drugs and the etiology of the disorders will be included. A review of empirically-validated treatments for drug and alcohol abuse will allow practitioners to identify effective interventions that can be incorporated into clinical practice.

**FOR DOCTORAL-LEVEL PSYCHOLOGISTS** who treat substance abusers or those who wish to add this proficiency to their practice.

### *THIS WORKSHOP IS DESIGNED TO HELP YOU:*

1. Identify the pharmacological characteristics of various drugs of abuse and understand how they influence a) abuse liability and b) detection of use during treatment.
2. Describe the prevalence of various types of drug abuse and identify different measures of harm due to their use.
3. Recognize how basic genetic and environmental risk factors influence liability to abuse drugs and how personality factors and psychiatric disorders influence this process.
4. Outline standards and methods of treatment outcome evaluation, and apply these standards and methods to critical analysis of treatment research reports.
5. Define the theoretical basis and empirical evidence supporting validated treatments for drug and alcohol abuse.
6. Utilize medications in the treatment of drug and alcohol abuse including methadone, naltrexone, disulfiram and nicotine replacement.

**LEADERS:** Maxine L. Stitzer, PhD, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD; Kathleen Carroll, PhD, Department of Psychiatry, Yale University School of Medicine, New Haven, CT; Roy W. Pickens, PhD, Addiction Research Center, National Institute on Drug Abuse, Baltimore, MD

**FEES:** Member/CPA Advance: \$155.00 On Site: \$180.00 **ENROLLMENT LIMIT:** 50 **CE CREDITS:** 7  
Non-member Advance: \$175.00 On Site: \$200.00 **TIME:** 9 a.m. - 5 p.m.

**DATE:** Friday, August 9, 1996

---

## 158 Practical Smoking Cessation Treatment: Combining Behavioral- and Pharmaco-Therapies -- Co-sponsored with APA Division 28

Four experts will present an overview of the current scientific understanding of smoking and nicotine dependence in this INTERMEDIATE workshop. They will provide pharmacological and cognitive-behavioral treatment strategies that support smoke-free living. This workshop will be partially funded by an educational grant from Marion Merrell Dow Pharmaceutical, Inc.

**FOR CLINICIANS** in practice settings who see clients who are smoking and want to consider quitting.

### *THIS WORKSHOP IS DESIGNED TO HELP YOU:*

1. Identify characteristics of the current smoking population;
2. Explain the scientific basis for currently recommended behavioral and pharmacological smoking cessation treatment approaches;
3. Apply principles of behavioral and cognitive therapy to the treatment of tobacco dependence including relapse prevention techniques;
4. Incorporate nicotine replacement therapy as an adjunct to smoking cessation treatment;
5. Identify settings in which smoking cessation treatment could profitably be offered; and
6. Conduct smoking cessation treatment in a private practice or as a consultant to industrial and/or health care organizations.

**LEADERS:** M. Marlyne Kilbey, PhD, Department of Psychology, Wayne State University, Detroit, MI; Maxine Stitzer, PhD, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD; Dorothy Hatsukami, PhD, Department of Psychiatry, University of Minnesota, Minneapolis, MN; Robert H. Shipley, PhD, VA Medical Center and Department of Psychiatry, Duke University School of Medicine, Durham, NC

**FEES:** Member/CPA Advance: \$155.00 On Site: \$180.00 **ENROLLMENT LIMIT:** 30  
Non-member Advance: \$175.00 On Site: \$200.00 **TIME:** 9 a.m. - 5 p.m.

**CE CREDITS:** 7

**DATE:** Tuesday, August 13, 1996

---

### Postdoctoral Positions

Available immediately on NIDA-supported projects investigating the behavioral neurobiology of cocaine, with special emphasis on receptor systems and brain regions associated with stress and the activation of the hypothalamic-pituitary-adrenal axis.

In particular, the effects of environmental stress and stress-related hormones on the acquisition and maintenance of intravenous cocaine self-administration, as well as on other behavioral effects of the drug, will be investigated. State of the art procedures including operant behavioral pharmacology, homogenate receptor binding and quantitative receptor autoradiography, and *in vivo* microdialysis and neurochemistry are available. Candidates must have a Ph.D. in Pharmacology, Neuroscience, Psychology or a related discipline with relevant laboratory experience. Send curriculum vitae and the names of three references to: Dr. Nick E. Goeders, Department of Pharmacology & Therapeutics, LSU Medical Center, P.O. Box 33932, Shreveport, LA 71130-3932. (e-mail: ngoe@lsu-mc.edu)

### POSTDOCTORAL POSITION

A postdoctoral position is available in the Psychobiology Section of the Intramural Research Program at the National Institute on Drug Abuse, Addiction Research Center. Research focuses on the behavioral and neurochemical effects of drugs of abuse and particularly, the pharmacological mechanisms that underlie the behavioral effects of abused drugs. Current emphasis is on the behavioral effects of cocaine and related stimulants. Behavioral studies examine psychomotor stimulant actions, discriminative stimulus effects, and reinforcing effects. Neurochemical studies include receptor binding, functional assays of neurotransmitter uptake, and regulation of second messenger function.

Applicants should have a strong interest in pharmacology and behavioral science and received a Ph.D. degree within the last five years. Interested individuals should send curriculum vitae to: Jonathan L. Katz, Psychobiology Section, NIDA Addiction Research Center, P.O. Box 5180, Baltimore, MD 21224, U.S.A. Telephone: 410/550-1533. E-Mail: jkatz@ip.nida.nih.gov

### Post-doctoral Training

It is anticipated that a post-doctoral training position will be available at the University of Maryland Department of Psychiatry in Baltimore beginning this summer. This 2-year position will focus on substance abuse in schizophrenia and severe mental illness. Demonstrated research productivity in substance abuse is required. Contact:

Alan S. Bellack, Ph.D.  
Professor of Psychiatry  
UMAB

685 W. Baltimore St  
Baltimore, MD 21201-1549  
e-mail: abellack@umabnet.ab.umd.edu

### NIAAA Training Grant Postdoctoral position

Available immediately. Salary would be \$19,608 for someone with zero years experience (new postdoc), \$20,700 - 1 year of relevant experience, and \$25,600 - 2 years of relevant experience. Insurance is paid for the postdoc only (no family members) at the rate of \$200 per month. Recent Ph.D.s in Pharmacology, Neuroscience, Biochemistry, or Molecular Biology are especially encouraged to apply. However, recent Psychology Ph.D.s with an interest in developing expertise in more molecular areas are also welcome. The work would be broadly related to developing an improved understanding of the bases for and possible methods of treating craving to ethanol and other drugs of abuse. Specific studies would involve regulation of recombinant dopamine and serotonin receptors stably expressed in clonal cells, and endogenously expressed receptors of several types expressed in astrocyte primary cultures and astrocyte clones. Extensive collaborative opportunities exist both with other Training Grant scientists and with other collaborators of Dr. Wilcox, both here at UT and at other institutions. Interested candidates should send their resumes and three letters of recommendation to: Richard E. Wilcox, Ph.D., Professor & Deluisio Fellow in Pharmacology, Neuropharmacology Program Head, Institute for Neuroscience, University of Texas, Wichita St., Austin, TX 78712-1074.

512-471-5199 (phone) — 512-475-6088 (FAX),  
wilcoxrich@mail.utexas.edu (Internet).

### POSTDOCTORAL TRAINING POSITIONS

Several postdoctoral research positions are open on NIDA training and research grants at the University of Texas Medical Branch. Project 1 involves the study of serotonin modulation of dopamine function and the hypothesis that the *in vivo* effects of cocaine are due in part to an imbalance in 5-HT/DA interactions. This project will combine microinjection and lesion techniques with *in vivo* electrophysiology and behavioral assessments. Project 2 concerns the hypothesis that programmed cell death underlies sensitization to chronic phenylthylamine and cocaine. The hypothesis will be validated *in vivo* using immunohistochemical and *in situ* hybridization techniques. The role of dopamine, glutamate and other transmitters will be determined in behavioral experiments and then modeled in primary cell culture in order to determine the signal transduction pathways. Project 3 concerns the role of sex and stress hormones in regulating the transcription of early response genes and how this may affect adaptive responses to drugs of abuse. Behavioral, biochemical, electrophysiological and molecular techniques will be used to address mechanistic and functional questions.

Ph.D. in pharmacology, neuroscience, cell biology or related discipline is required. Demonstrated expertise in one of the major techniques will be considered favorably. Please contact either:

Dr. Kenneth M. Johnson  
(kjohnson@beach.utmb.edu) or

Dr. Kathryn A. Cunningham  
(cunningham@beach.utmb.edu)

Department of Pharmacology and Toxicology,  
University of Texas Medical Branch, Galveston,  
TX 77555-1031.

### Postdoctoral Position

Available July 1, 1996 to study the sympathetic nervous system (SNS) innervation of white adipose tissue (WAT). The ideal candidate for this NIH-funded position (available for up to four years) will hold a Ph.D. in Behavioral Neuroscience, Neuroscience, Zoology or Psychobiology and will have experience with immunocytochemical methodologies. Salary will be commensurate with experience. Send vita and names of three references to: Dr. Timothy J. Bartness, Depts of Psychology and of Biology, Georgia State University, Atlanta GA 30303 or send via e-mail to: peyjb@gsu.edu

Postdoc available to work on use-dependent neurochemical events associated with recovery of function after brain injury, in the lab of Timothy Schallert, University of Texas at Austin. Appointment by June 1, 1996, to start by July 1, 1996. Contact Tim Schallert for further details. Tschallert@mail.utexas.edu 512-471-6141.

### JOHNS HOPKINS SUBSTANCE ABUSE RESEARCH

Postdoctoral human research positions available in a stimulating and productive environment with excellent clinical and research resources. Human Laboratory Behavioral Pharmacology. Design and implement controlled laboratory research on the behavioral, subjective, and physiological effects of psychoactive drugs for abuse liability testing and medications development. Drug classes under study include: opioids, cocaine, anxiolytics, caffeine, nicotine. Research background and experience required. Applied Research in Behavioral Treatment of Substance Abuse. Develop and evaluate treatment interventions for opioid and cocaine abusers. Sites include methadone, outpatient drug-free and addiction/pregnancy clinics. Minorities encouraged. USPHS stipend levels based on experience. Send vita, letter of interest, and names/phones of 3 references to: George E. Bigelow, Ph.D. or Maxine L. Stitzer, Ph.D.: BPRU, Behavioral Biology Research Center, 5510 Nathan Shock Drive, Johns Hopkins Bayview Campus, Baltimore, Maryland 21224-6823. (410) 550-0035.

### RESEARCH ASSOCIATE

The Nicotine Research Laboratory in the University of Michigan Department of Psychiatry has an opening for a Research Associate to serve as Coordinator of a federally-funded laboratory investigation of smoking and depression in women. Candidates should have Ph.D. in psychology or related field; salary commensurate with training and experience. Send letter of interest and CV to:

C.S. Pomerleau, Ph.D.  
Nicotine Research Laboratory  
Behavioral Medicine Program  
University of Michigan  
Department of Psychiatry  
475 Market Place, Ste L  
Ann Arbor, MI 48108

The University of Michigan is an Equal Opportunity/Affirmative Action employer

## Division 28 Officers:

	Name	Term	E-mail Address
<b>Elected:</b>			
President	Stephen C. Fowler	8/94-8/97	fowler@falcon.cc.ukans.edu
President-elect	Marlyne Kilbey	8/95-8/98	MKILBEY@sun.science.wayne.edu
Past President	John G. Grabowski	8/93-8/96	jgrabows.utmsimail@msi66.msiuth.tmc.edu
Council Representative	Alice M. Young	2/94-2/97	ayoung@sun.science.wayne.edu
Members-at-Large	James L. Sorenson	8/93-8/96	james@itsa.ucsf.EDU
	Harriet de Wit	8/94-8/97	hdew@midway.uchicago.edu
<b>Appointed:</b>			
Program Chair	Kimberly Kirby	8/95-8/97	se18@columbia.edu
Past Program Chair	Suzette Evans	8/94-8/96	zaen@midway.uchicago.edu
Newsletter Editor	James P. Zaeny	8/93-8/96	ator@BPRU.UUCP.JHU.EDU
ASPET/Neurosci Liaison	Nancy Ator	8/93-8/96	bigelow@BPRU.UUCP.JHU.EDU
APA Pub Aff Liaison	George E. Bigelow	8/91-8/96	doverton@VM.TEMPLE.EDU
APS Liaison	Donald A. Overton	8/91-8/96	wood@SFCLU.MED.NYU.EDU
BSA	Ronald W. Wood	8/92-8/96	barryh@VMS.CIS.PITT.EDU
Centennial Officer	Herbert Barry	8/91-8/96	hatsu001@maroon.tc.umn.edu
CPDD Liaison	Dorothy Hatsukami	2/95-2/98	sannerud@justice.usdoj.edu
Com. on Animal Research	Christine Sannerud	8/93-8/96	mstilzer@BPRU.UUCP.JHU.EDU
Com. on Cont. Educ.	Maxine L. Stitzer	8/95-8/98	woolverton@fiona.unsmmed.edu
Com. On Nomt. & Awards	Bill Woolverton	8/95-8/98	MKILBEY@WAYNESTI
Com. on Prescrip. Priv.	Marlyne Kilbey	8/91-8/96	
Corporate Liaison	James E. Barrett	8/85-8/98	rspiga.utmsimail@msi66.msiuth.tmc.edu
Membership Chair	Ralph Spiga	5/96-5/99	mcarroll@STAFF.TC.UMN.EDU
New Fellows Chair	Marilyn Carroll	8/85-8/98	slechts@envmed.ROCHESTER.EDU
Neurobeh. Tox. Com.	Deborah Cory-Slechta	8/93-8/96	kperkins@vms.cis.pitt.edu
Public Information	Kenneth A. Perkins	8/82-8/96	dpenetar@natick-ccmail.army.mil
Secretary	David M. Penetar	8/92-8/96	jacri@irp.nida.nih.gov
Treasurer	Jane B. Acri	1/96-1/99	mazure@BIOMED.MED.YALE.EDU
Women's Network Rep.	Carolyn M. Mazure	8/93-8/96	

**James P. Zaeny**  
**Editor, Division 28 Newsletter**  
**Department of Anesthesia & Critical Care**  
**MC4028**  
**5841 S. Maryland Avenue**  
**University of Chicago**  
**Chicago, IL 60637**

00010444951 FCS0 2954  
 DR VICTOR G LATTES  
 SCH OF MED  
 UNIV OF ROCHESTER BOX EHSJ  
 ROCHESTER NY 14642

